Showing 3101-3110 of 4063 results for "".
- Visionix USA to Debut VX 40 Couture Auto Lensmeter at Vision Expo Westhttps://modernod.com/news/visionix-usa-to-debut-vx-40-couture-auto-lensmeter-at-vision-expo-west/2484141/Visionix USA will unveil its latest innovation—the VX 40 Couture—at Vision Expo West, September 18–21 at the Venetian Expo Center in Las Vegas. According to Visionix, the VX 40 Couture is a next-
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- FDA Extends Target Action Dates to Fourth Quarter for Two Eylea HD Submissionshttps://modernod.com/news/fda-extends-target-action-dates-to-fourth-quarter-for-two-eylea-hd-submissions/2484126/Due to problems identified in a general FDA inspection of its third-party contract manufacturer, the FDA has extended the target action dates to the fourth quarter of 2025 for two Eylea HD (aflibercept injection 8 mg) regulatory submissions. The submissions include a prior-approval
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- Beyeonics Vision Secures US Patent for Ophthalmic Surgical Visualization Technologyhttps://modernod.com/news/beyeonics-vision-secures-us-patent-for-ophthalmic-surgical-visualization-technology/2482931/Beyeonics Vision announced the issuance of a US patent to protect its core technology for how surgeons visualize the eye during cataract and other ocular procedures. According to Beyeonics, the patent, titled “Systems and Methods for Imaging a
- First FDA-Approved Treatment for MacTel Performed; Dr. Wykoff Shares Experiencehttps://modernod.com/news/first-fda-approved-treatment-for-mactel-performed/2482928/Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure for its encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey). Encelto was approved in March 2025 as the first and only FDA
- 4DMT Provides New 60-Week Results for Gene Therapy Candidate for DMEhttps://modernod.com/news/4dmt-provides-new-60-week-results-for-gene-therapy-candidate-for-dme/2482922/4D Molecular Therapeutics (4DMT) announced interim results from its SPECTRA phase 2a clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data were presented at the 43rd Annual American Society of Retina Specialists (ASRS) scientific mee
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Reciprocal Tariffs Take Effect: What Eye Care Professionals Need to Knowhttps://modernod.com/news/reciprocal-tariffs-take-effect-august-7-what-eye-care-professionals-need-to-know/2482916/Eye care professionals and optical businesses across the US are bracing for major changes as the White House prepares to implement new reciprocal tariffs on imported goods from key trade partners beginning August 7, 2025. The tarriffs come following a temp
- Lenz Therapeutics Receives FDA Approval of VIZZ for the Treatment of Presbyopiahttps://modernod.com/news/lenz-therapeutics-receives-fda-approval-of-vizz-for-the-treatment-of-presbyopia/2482912/A new, first-of-its kind presbyopia drop will soon be available in the US as the FDA approved Lenz Therapeutics' VIZZ (aceclidine ophthalmic solution) 1.44%. Expected to be broadly available in the fourth quarter of 2025, VIZZ is the first and only FDA-approved aceclidine-based